Core Viewpoint - The article discusses the fraudulent practices of Nohui Health, revealing that the company engaged in significant sales data manipulation, leading to its impending liquidation and delisting from the stock market [2][3][12]. Group 1: Fraudulent Practices - Nohui Health was found to have fabricated sales performance, employing methods such as purchasing fecal samples from sanitation workers and splitting samples among fake testing accounts [3]. - The company's top management was aware of and led the fraudulent activities, with only a few executives allowed to attend confidential sales strategy meetings [3]. - In 2022, Nohui Health's sales team reported a 260% revenue growth, with sales figures soaring from 200 million to 760 million yuan, despite adverse conditions like the pandemic [8]. Group 2: Consequences of Fraud - The fraudulent practices led to Deloitte's withdrawal from auditing the company, resulting in a series of negative events including stock suspension and executive resignations [2][3]. - A significant short-selling report by CapitalWatch triggered a dramatic drop in Nohui Health's stock price, from a peak of 38.95 HKD to 15.7 HKD [12][13]. - The company is now in the process of liquidation, with a court hearing scheduled for November 14, where over 4,000 individual investors are seeking compensation for their losses, totaling over 700 million yuan [15][16]. Group 3: Internal Dynamics - The sales team operated under immense pressure to meet targets, leading to a culture of manipulation and risk-taking [9][10]. - Weekly sales meetings were highly confidential, with only select personnel allowed to attend, emphasizing the secretive nature of the operations [9]. - The shift towards compliance in 2023 has led to a restructuring of sales channels, but the legacy of fraudulent practices remains a significant issue for the company [11].

中国经济网北京10月9日讯 近日，平安基金管理有限公司发布关于旗下基金估值调整情况的公告。 公告称，平安基金管理有限公司（以下简称"本公司"）决定自2025年9月30日起，对公司旗下证券 投资基金持有的"诺辉健康"（股票代码：6606.HK）进行估值调整，按照0.01港元/股进行估值。公司将 密切关注上述股票后续经营情况及其他重大事项，进行合理评估，谨慎确定其估值价格。 （责任编辑：康博） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 諾輝健康 | | | | | | 呈交日期: | 2025年10月8日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 06606 | 說明 | 普通股 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00005 | USD | | 50,000 | | 增加 / 減少 (-) | ...

Core Points - Huatai Fund Management Co., Ltd. announced an adjustment in the valuation of certain funds under its management, specifically regarding the stock of Nohow Health (stock code: 6606.HK) [1] - The valuation adjustment will take effect from September 26, 2025, with the stock being valued at HKD 0.01 per share [1]

（责任编辑：康博） 公告称，创金合信基金管理有限公司经与基金托管人协商一致，自2025年9月26日起，对我司旗下 证券投资基金持有的"诺辉健康（证券代码：6606.HK）"按照0.01港元/股进行估值。 中国经济网北京9月29日讯 近日，创金合信基金管理有限公司发布关于公司旗下部分基金估值调整 情况的公告。 ...

Group 1 - The core point of the announcement is that Xingyin Fund Management Co., Ltd. has decided to adjust the valuation method for its holdings in "Nohow Health" stock, effective from September 26, 2025 [1] - The valuation for the "Nohow Health" stock (stock code: 6606.HK) held by the Xingyin CSI Hong Kong Stock Connect Technology ETF (fund code: 513560) will be set at HKD 0.01 per share [1]

根据《中国证券监督管理委员会关于证券投资基金估值业务的指导意见》（中国证券监督管理委员会公 告[2017]13号）的相关规定，经与基金托管人协商一致，兴银基金管理有限责任公司（以下简称"本公 司"）自2025年9月26日起，决定对兴银中证港股通科技交易型开放式指数证券投资基金（基金代码： 513560）所持有的"诺辉健康"（证券代码：6606.HK）按照0.01港元/股进行估值。 待上述股票体现出活跃市场交易特征后，将恢复为采用当日收盘价格进行估值，届时将不再另行公告。 敬请投资者予以关注。 投资者可通过以下途径咨询有关详情： 本公司网站：www.hffunds.cn 客户服务电话：40000-96326 风险提示：本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈利，也 不保证最低收益。基金的过往业绩并不预示其未来表现。投资者投资于本公司管理的基金时应认真阅读 《基金合同》《招募说明书》等法律文件，并注意投资风险。 特此公告。 兴银基金管理有限责任公司 ■ 2.与分红相关的其他信息 ■ 3.其他需要提示的事项 （1）权益登记日申请申购或转换转入的基金份额不享有本次分红权益，权益登记日 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 諾輝健康 | | | | | | 呈交日期: | 2025年9月3日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 06606 | 說明 | 普通股 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.00005 | USD | | 50,000 | | 增加 / 減少 (-) | | ...

Group 1 - The company, Nohow Health (06606), received a letter from the Stock Exchange on August 12, 2025, outlining additional resumption guidance [1] - The guidance includes the removal of the liquidator's appointment and the requirement to comply with listing rules 3.10(1), 3.25, 3.27A, and 13.92 [1] - A hearing regarding the liquidation petition is scheduled for November 14, 2025, at 10:00 AM (Cayman time) in the Grand Court [1]

Core Viewpoint - Nohow Health (06606) has received additional resumption guidance from the Stock Exchange, indicating steps towards lifting the appointment of liquidators and compliance with specific listing rules [1] Group 1 - The company received a letter from the Stock Exchange on August 12, 2025, outlining additional resumption guidance [1] - The guidance includes the removal of the liquidator's appointment and the need to comply with listing rules 3.10(1), 3.25, 3.27A, and 13.92 [1] - A hearing regarding the liquidation application is scheduled for November 14, 2025, at 10:00 AM (Cayman time) in the Grand Court [1]